SupremeToday Landscape Ad
Back
Next
Judicial Analysis Court Copy Headnote Facts Arguments Court observation
Listen Audio Icon Pause Audio Icon
judgment-img

2018 Supreme(Del) 3010

IN THE HIGH COURT OF DELHI AT NEW DELHI
S. RAVINDRA BHAT, A.K. CHAWLA, JJ.
Cadila Healthcare Limited And Anr. – Appellants
Versus
Competition Commission of India And Ors. – Respondents
LPA 160 of 2018 & CM APPL. Nos. 11741-44 of 2018
Decided On : 12-09-2018

Advocates Appeared:
For the Appellant : Mr. Krishnan Venugopal, Mr. Rahul Goel and Ms. Anu Monga, Mr. Neeraj Lalwani, Mr. Rishabh Arora and Mr. Nitish Sharma
For the Respondents: Mr. Samar Bansal, Ms. Shreya Singh, Mr. Manan Shishodia and Ms. Aakansha Kaul

The CCI has the power to recall/review the order under Section 26(1) of the Competition Act but within the parameters and subject to the restrictions discussed in the judgment.

Headnote:

The Competition Commission of India (CCI) has the power to recall/review the order under Section 26(1) of the Competition Act but within the parameters and subject to the restrictions discussed in the judgment.

Fact of the Case:

The case involves an appeal against the judgment of a single judge of the High Court, which upheld the orders of the CCI. The CCI had rejected the appellant's (Cadila) review/recall application and its application for cross-examination. Cadila had alleged that the CCI had erred in proceeding with the investigation against it without a separate order under Section 26(1) of the Act, that the investigation was vitiated due to fraud, and that the CCI had erred in rejecting its application for cross-examination.

Finding of the Court:

The court held that the CCI has the power to recall/review the order under Section 26(1) of the Act but within the parameters and subject to the restrictions discussed in the judgment. The court also held that the CCI did not err in rejecting Cadila's review/recall application and that the CCI erred in refusing to grant cross-examination (to Cadila) of the three witnesses who had deposed before the DG.

Issues: (1) Whether the DG's investigation in the absence of a specific order under Section 26(1) by CCI having formed a prima facie opinion, is vitiated; (2) Is the impugned judgment correct in upholding as sound CCI's finding rejecting the recall application, (based on grounds of fraud, res judicata and/or no cause of action). (3) Whether there was denial of principles of natural justice in the rejection of Cadila's request for cross examination; (4) Whether DG could have issued notice to Cadila's officials under Section 48

Ratio Decidendi: (1) The court held that the DG's investigation in the absence of a specific order under Section 26(1) by CCI having formed a prima facie opinion, is not vitiated. The court reasoned that the purpose of the investigation is to cover all necessary facts and evidence in order to see as to whether there are any anti-competitive practices adopted by the persons complained against. For this purpose, the starting point of inquiry would be the allegations contained in the complaint. However, while carrying out this investigation, if other facts also get revealed and are brought to light, revealing that the 'persons' or 'enterprises' had entered into an agreement that is prohibited by Section 3 which had appreciable adverse effect on the competition, the DG would be well within his powers to include those as well in his report. (2) The court held that the impugned judgment is correct in upholding as sound CCI's finding rejecting the recall application. The court reasoned that the CCI has the power to recall/review the order under Section 26(1) of the Act but within the parameters and subject to the restrictions discussed in the judgment. The court also held that the CCI did not err in rejecting Cadila's review/recall application because the recall application was filed after the DG's report to CCI and the conclusion of the court in Google Inc. (supra) has to be read/understood to mean a recall/review application can be filed during investigation and not after the submission of the report by the DG. (3) The court held that there was denial of principles of natural justice in the rejection of Cadila's request for cross examination. The court reasoned that the CCI erred in refusing to grant cross-examination (to Cadila) of the three witnesses who had deposed before the DG. The court held that the reasons given by the CCI for denying the request for cross examination are not germane and that the discretion, which is undoubtedly vested with the CCI to permit or refuse cross examination of a witness, is to be exercised judiciously. (4) The court held that the DG could have issued notice to Cadila's officials under Section 48. The court reasoned that the correct interpretation of law was given in Pran Mehra the reasoning of which is hereby confirmed, as is the reasoning in Ministry of Agriculture v. M/s Mahyco Monsanto Biotech Ltd, which proceeds on a correct appreciation of the law.

Final Decision: The appeal succeeds in part and is allowed to the extent that CCI shall afford opportunity to cross examine the three individuals named by Cadila in its application (dated 08.01.2018) by issuing a notice to all concerned. On all other aspects the appeal, i.e. as to rejection of the recall application and the other points discussed above, has to fail and is dismissed.

JUDGMENT :

S. RAVINDRA BHAT, J.

1. The present appeal is directed against a judgment and order dated 09.03.2018 of a learned Single Judge of this court. The impugned judgment upheld the orders dated 16.01.2018 and 17.01.2018 passed by the first Respondent i.e. Competition Commission of India (hereinafter “CCI”). The CCI’s orders were passed on the two review/recall applications and application for cross examination filed by the first Appellant (hereafter “Cadila”). The applications filed by Cadila sought recall of the CCI’s order dated 17.11.2015 under Section 26(1) of the Competition Act, 2002 (“the Act” hereafter). Those directions regard were that “in the course of investigation, if involvement of any other party is found, the DG shall investigate the conduct of such other parties who may have indulged in such contravention".

2. Cadila’s review/recall application was preferred on 8th September 2017. Two subsequent reminder applications were also filed by Cadila on 08.11.2017 and 29.11.2017. By the CCI’s order of 12.12.2017, Cadila was directed to urge on the merits of the review/recall application at the time of the final hearing on 16.01.2018. The opposite parties directed to file their responses to the DG report by 05.01.2018. Hearing was deferred from 12.12.2017 to 16.01.2018 and 17.01.2018 in terms of the CCI’s order dated 21.11.2017. Cadila filed its common reply to the investigation report submitted by the respondent Director General (“DG” hereafter), on 08.01.2018 before the CCI. It specifically requested that its application for Review/Recall be heard separately and urged CCI to pass a separate order in this regard since - in case the same were allowed–it may not have to undergo the proceedings under the Competition Act.

3. The CCI delivered its orders on 16.01.2018 and 17.01.2018, rejecting Cadila’s review/recall application, Cadila urges that these orders were dispatched on or after 09.02.2018 and received on (13)14.02.2018. The impugned judgment upheld CCI’s orders dated 16-17.01.2018.

Necessary Facts

4. Three information petitions/complaints were preferred by - (a) M/s Alis Medical Agency (“AMA”), b) M/s Stockwell Pharma, Surat (“SP”) and c) M/s Apna Dawa Bazar, Vadodara (“ADB”) before the CCI. Those three entities alleged that they were denied supplies of medicines, when they approached certain pharmaceutical companies, or their clearing and forwarding agents, on the alleged directions of the Federation of Gujarat State Chemist and Druggists Association (“the federation” hereafter) in the State of Gujarat. One Dayabhai Patel was a partner in both ADB and Reliance Medical Agency (“RMA”). It was alleged that Dayabhai Patel had filed another case -in the CCI- on a similar issue through another firm Reliance Agency (“RA” hereafter). One Nayan Raval, the Authorized Signatory of the third respondent RMA was also a partner in ADB and RA.

5. Cadila alleged that RMA prepared a pay order bearing No. 371845 dated 09.07.2015 for Rs. 50,000/- in favour of CCI for filing the information. By letter dated 09.07.2015 RMA approached Cadila through its C&F Agent i.e. the second petitioner, seeking supply of certain pharmaceutical products. On 03.08.2015, the second information petition dated 27.07.2015 was filed by RMA (Case No. 68/2015 before the CCI) against the Chemist & Druggist Association, Vadodara and certain pharmaceutical companies including Cadila, alleging limiting and control supply of drugs in Vadodara by requiring “No Objection Certificate” for appointment of stockists. It was alleged that Dayabhai Patel a partner in Apna Dawa Bazar, is also partner in RMA.

6. On 26.08.2015, CCI took cognizance of the information, by an order and called upon RMA to explain its case on 30.09.2015. It is alleged that none of the writ petitioners were informed about this or called for hearing. Cadila alleged that it received balance payment of Rs. 3,25,000/- (for the order dated 09.07.2015) on 24.09.2015. Cadila stated that it fulfilled the or









































































































































































































Click Here to Read the rest of this document

1
2
3
4
5
6
7
8
9
10
11
Judicial Analysis

AI

SupremeToday Portrait Ad
supreme today icon
logo-black

An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers

Please visit our Training & Support
Center or Contact Us for assistance

qr

Scan Me!

India’s Legal research and Law Firm App, Download now!

For Daily Legal Updates, Join us on :

whatsapp-icon Back to top